Patents by Inventor Chung-leung Chan

Chung-leung Chan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12230266
    Abstract: Techniques for routing data, in a system including multiple assistants, are described. A user device may store configuration data for a virtual assistant, where the configuration data includes a virtual assistant identifier, one or more resource identifiers, and optionally a virtual assistant name. A resource identifier may correspond to a component or device(s) of the virtual assistant. When the user device receives event data associated with a virtual assistant identifier, the user device may use stored configuration data to determine a resource identifier(s) associated with the virtual assistant identifier, associated with the event data. The user device may thereafter send the event data to the component and/or device(s) corresponding to the determined resource identifier(s).
    Type: Grant
    Filed: September 30, 2022
    Date of Patent: February 18, 2025
    Assignee: Amazon Technologies, Inc.
    Inventors: David Henry, Kenneth Chung Leung Chan, Akshai Gopalakrishnan Prabhu, Yilin Zhu, Alain Soquet
  • Publication number: 20170275348
    Abstract: Homogeneous preparations of human and murine IL-31 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity.
    Type: Application
    Filed: June 6, 2017
    Publication date: September 28, 2017
    Inventors: Lowell J. Brady, Thomas R. Bukowski, Chung-leung Chan
  • Patent number: 9732143
    Abstract: Novel materials and methods useful for expressing heterologous proteins in prokaryotic cells are provided, including prokaryotic cells expressing FkpA and/or Skp.
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: August 15, 2017
    Assignee: XOMA TECHNOLOGY LTD.
    Inventors: Raphael D. Levy, Chung-Leung Chan, Kiranjit K. Ahluwalia, Toshihiko Takeuchi
  • Publication number: 20170096466
    Abstract: Homogeneous preparations of human and murine IL-31 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity.
    Type: Application
    Filed: December 16, 2016
    Publication date: April 6, 2017
    Inventors: Lowell J. Brady, Thomas R. Bukowski, Chung-leung Chan
  • Publication number: 20160347809
    Abstract: Homogeneous preparations of human and murine IL-31 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity.
    Type: Application
    Filed: July 19, 2016
    Publication date: December 1, 2016
    Inventors: Lowell J. Brady, Thomas R. Bukowski, Chung-leung Chan
  • Publication number: 20150010500
    Abstract: Homogeneous preparations of human and murine IL-31 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity.
    Type: Application
    Filed: September 4, 2014
    Publication date: January 8, 2015
    Inventors: LOWELL J. BRADY, THOMAS R. BUKOWSKI, CHUNG-LEUNG CHAN
  • Publication number: 20140154743
    Abstract: Novel materials and methods useful for expressing heterologous proteins in prokaryotic cells are provided, including prokaryotic cells expressing FkpA and/or Skp.
    Type: Application
    Filed: February 3, 2012
    Publication date: June 5, 2014
    Inventors: Raphael D. Levy, Chung-Leung Chan, Kiranjit K. Ahluwalia, Toshihiko Takeuchi
  • Publication number: 20130149279
    Abstract: Homogeneous preparations of human and murine IL-31 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity.
    Type: Application
    Filed: April 27, 2011
    Publication date: June 13, 2013
    Inventors: LOWELL J. BRADY, THOMAS R. BUKOWSKI, CHUNG-LEUNG CHAN
  • Patent number: 7858341
    Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of FGF18 are described. The vectors utilize the FGF18 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Using the expression vectors, the FGF18 gene was produced in E. coli to a level of greater than 1 g/L in fed batch fermentation. Also included are OmpT deficient E. coli strains, as well as OmpT and fhuA negative strains transformed with an FGF18 expression vector.
    Type: Grant
    Filed: December 12, 2005
    Date of Patent: December 28, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Brian J. Reardon, Susan H. Julien, Chung-leung Chan, Hong Y. Liu
  • Publication number: 20100297065
    Abstract: Homogeneous preparations of human and murine IL-31 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity.
    Type: Application
    Filed: June 4, 2009
    Publication date: November 25, 2010
    Inventors: LOWELL J. BRADY, THOMAS R. BUKOWSKI, CHUNG-LEUNG CHAN
  • Patent number: 7595174
    Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
    Type: Grant
    Filed: October 17, 2006
    Date of Patent: September 29, 2009
    Assignee: ZymoGenetics, LLC
    Inventors: Lowell J. Brady, Kevin M. Klucher, Chung-leung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
  • Patent number: 7544779
    Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
    Type: Grant
    Filed: October 13, 2006
    Date of Patent: June 9, 2009
    Assignee: ZymoGenetics, LLC
    Inventors: Lowell J. Brady, Kevin M. Klucher, Chung-leung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
  • Patent number: 7468423
    Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
    Type: Grant
    Filed: October 13, 2006
    Date of Patent: December 23, 2008
    Assignee: ZymoGenetics, Inc.
    Inventors: Lowell J. Brady, Kevin M. Klucher, Chung-leung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
  • Publication number: 20060228329
    Abstract: Homogeneous preparations of human and murine IL-31 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity.
    Type: Application
    Filed: January 30, 2006
    Publication date: October 12, 2006
    Inventors: Lowell Brady, Thomas Bukowski, Chung-leung Chan